Early Phase 1 Rare Disease Trial, Recruiting NCT06860672 Sponsor: Yongguo Yu Condition: Rare Disease
Back to Rare Disease

Early Phase 1 Rare Disease Trial, Recruiting

NCT06860672
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Snijders Blok-Campeau syndrome
  • You have a specific genetic change (mutation) in the CHD3 gene identified as c.3073C>T, p.(Arg1025Trp)
  • Your liver, heart, and immune system are all functioning normally
  • Your blood clotting and platelet levels are within normal range

Who may not be able to join:

  • You have a brain tumor or any growth or mass inside the skull
  • You have a medical reason why a lumbar puncture (spinal tap) or injection into the spinal canal cannot be safely performed
  • You have ongoing or hard-to-control epileptic seizures
  • You have an unstable or active infection, including bacterial, fungal, HIV, hepatitis A, or hepatitis B
  • A blood test shows a high level of antibodies against the therapy's delivery vehicle (AAV), above a specific threshold (confirm with trial site)
  • You have received immune-system-affecting medications (other than those allowed by the study) within the past 3 months
  • You have previously received any gene therapy treatment
  • You are currently in another clinical trial or have taken an experimental treatment within the past 30 days (or within 5 half-lives of that treatment)
  • You have a known allergy to any of the products used in this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Yongguo Yu, Dr, MD, PhD, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Phone: +86-25-25076466

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Yongguo Yu
Registry
ClinicalTrials.gov
Start date
19 February 2025
Est. completion
1 April 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of drug-related serious adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov